Transcript CyteVice - Purdue University

CyteVice
“Discover the discovery”
Alvin Dabhi
Aditya Sai
5/1/2013
The Opportunity



Fatty liver diseases have been linked to diabetes and obesity; affect
6 million people in the US and approximately 10-20% of Americans
have significant liver fat content
Global drug discovery market was $41.4 billion in 2012, with high
throughput screening comprising approximately 30% of the market;
this equates to a $1.3 billion market segment to be tapped within the
fatty liver drug market
A potential drug costs between $55 million to $1.3 billion to bring to
market; contracting the drug discovery phase will save time and
money for companies
Discovery
(5 years)
Preclinical
(2 years)
Clinical
(6 years)
Marketing
The Product





CyteVice is a diagnostic tool
capable of screening for the best
agents to defat candidate livers
Specially coated 96 well plate
assays that can be fitted for manual
or automated use
Prepackaged cells sustained within
device to allow for more targeted
testing
>85% cell viability maintained
Proprietary content: Patent
Pending
Market Description



Pharmaceuticals
 Key customers in the liver defatting market
 Potential Market Size: $125 million
Academic Research labs
 Select researchers may find product desirable
 Potential Market Size: $50 million
Potential growth opportunities available in other
diseases that can be screened and treated in
similar manner (obesity, Hepatitis C, etc.)
Competitive Edge
CyteVice
Competitors (ForteBIO,
EVOTec)
Direct Application to Liver
Disease
Specifically targeted
Not targeted to specific
disease
Usage of Cells
Specialized cells within
each plate with necessary
reagents
None
Cell Viability
Above Average
Average
Precision
>99% reproducible results
Closest competitor has
~85% precision
Shelf Life
6 months
2-3 months
“Viability Assurance”
Included with every device None
Business Model
Offer screening devices to our customers
 Product Selling Points

Preset cells, reagents
 “Viability Assurance”


Negotiate volume contracts with key
resource providers, such as Life
Technologies® and BD Biosciences®, at
lowest possible cost
Our Team
Key Members:
 CEO: Carlton Jones


CFO: Wendy DiCicco


Long history as finance chief in biotechnology and medical
device startups
COO: Shannon Dahl, Ph.D.


3 decades of experience in developing innovative
instrumentation and consumables
Operations officer in tissue engineering company
Principal Board Advisor: Dr. Francois Berthiaume, Ph.D.

Well versed in liver defatting methodologies and hepatocyte
models
Investment Request
2 infusions of $1,000,000 and
$200,000 respectively
 $10.5 million exit value at year 6
 Investments will go into:

hiring of technicians and scientists: $500,000
 procurement of starting materials: $150,000
 capital & property expenditures: $150,000
 pilot production: $150,000
 marketing, press releases, webinars,
conference events, sales representatives:
$250,000

Financial Summary
Projected Revenues and Incomes for 3
Years After Launch
Dollars ( Thousands of $s)
3,500
3,000
Projected
Cost Per
Device:
$80
Projected
Retail Price
Per Device:
$250
2,500
Projected Net
Revenue
2,000
1,500
Projected Net
Income
1,000
500
0
Year 1
Year 2
Year 3
Projected
Net Present
Value:
$2,046,000
Product Timeline
Year 1
• Secure first infusion of $1,000,000
• Design coating protocol & hire technicians
• Procurement of resources from suppliers
2
• Construct pilot plant
• Finalize coating protocol & hire scientists
• Publicize product in research papers, webinars, etc.
3
• Pilot production
• Secure second infusion of $200,000
• Begin selling purchase orders to customers
4
• Aggressive direct marketing to potential customers
• Research alternative cell and capacity models
5
• Begin production of alternate products & expand
pipeline
Summary and Q&A

CyteVice has an important role in the drug discovery
market within the area of fatty liver disease






No established screening tool used in testing
Addresses vital need in drug discovery
Specialized platform to conduct high throughput cell
based assays
Selling prepackaged cells along with assays
Expansion to incorporate other tissue types and
therapeutics
Ambitious startup with experienced advisors seeking
investment for a transformative product to
revolutionize drug screening